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ABSTRACT 
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous 
system (CNS).  Childhood vitamin D insufficiency is a known risk factor of MS.  However, it 
remains unclear how vitamin D levels before adolescence affect the susceptibility to disease.  We 
hypothesize that vitamin D increases IL-34 production, which directs microglia into an anti-
inflammatory phenotype, preventing neurodegeneration in a developing CNS.  We observed an 
increased expression of IL-34 mRNA in primary neurons and neurons derived from a mouse 
Neuroblastoma (N2a) cell line after treating with calcitriol, the biologically active form of 
vitamin D.  Additionally, immortalized murine microglia (BV-2) and primary microglia treated 
with IL-34 showed a decrease in pro-inflammatory cytokines and an increase in anti-
inflammatory molecules compared to untreated controls upon lipopolysaccharide (LPS) 
stimulation.  These findings indicate that microglia can be directed to an anti-inflammatory 
phenotype by IL-34, which is produced by vitamin D-treated neurons.  To study how vitamin D 
signaling in childhood influences the risk of developing disease in vivo, we generated a 
transgenic mouse model using single-neuron labeling with inducible Cre-mediated knockout 
(SLICK) mice.  This allows manipulation of VDR levels on neurons during different ages of life.  
We found that SLICK f/+ mice have decreased VDR expression when evaluated by 
immunohistochemistry.  These mice showed that low levels of vitamin D during development 
caused increased disease severity through inducing experimental autoimmune encephalomyelitis 
(EAE).  By understanding the mechanism by which vitamin D levels influence multiple sclerosis 
susceptibility, vitamin supplements could be administered to prevent high risk populations from 
developing this incurable disease. 
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INTRODUCTION 
 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) 
caused by auto-reactive T lymphocytes (T-cells) which recognize self myelin as foreign.  This 
autoimmune disease causes neurodegeneration by damaging the myelin sheath and axons, 
interrupting the signals through these myelinated nerves.  Symptoms of MS include vision loss, 
incontinence, pain, depression, and eventually a decrease in motor function.  Disease onset is 
typically 20-40 years of age.  In addition, there is no cure for MS and the treatments are very 
expensive.  Our goal is to find a pathway that causes an increase in MS disease susceptibility 
that can be manipulated in order to prevent disease onset. 
Multiple sclerosis affects 2.5 million people worldwide
1
 and an estimated 400,000 people 
in the United States
2
.
 
 Additionally, the prevalence of MS is increasing worldwide.  Each year 
MS costs the United States more than $10 billion
2
, and the disease costs each patient an average 
of $47,000 a year
3
.  The high cost of MS makes prevention essential.  Considering the risk 
factors of MS, vitamin D could be easily and cost effectively implemented into diets of at risk 
patients.  This could then help to decrease the risk of disease onset later in life.  Currently, there 
is no way to prevent MS, so finding a way to decrease disease onset is a critical step in 
addressing this costly and devastating disease.  Additional research would lead to the implication 
of a new public health policy to increase vitamin D levels in people with high MS susceptibility. 
Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis:  The disease 
course of MS is clinically observed as both a relapsing/remitting and progressive disease.  In the 
relapsing/remitting form of the disease, the patients have relapses of neurological dysfunction 
followed by a period of full or partial remission of these defects.  This later develops into a 
secondary progressive phase where there is a continuous decrease in neurological function.  
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Some patients begin with this progressive form of MS which is identified as primary progressive 
multiple sclerosis.  During disease, auto-reactive immune cells and microglia cause 
inflammation, myelin damage, and eventually axonal death.  MS is commonly studied using 
experimental autoimmune encephalomyelitis (EAE).  This animal model of MS resembles the 
disease and is caused by an immune response targeting the neurons.  B6, B10.PL, and SJL mice 
are common breeds of mice, which can be easily induced to develop EAE.  However EAE 
susceptibility and disease course does vary based on the mouse strain.  EAE is induced by 
immunization with myelin proteins emulsified in complete Freund’s adjuvant (CFA) or adoptive 
transfer of myelin specific CD4+ cells
4
.  The steps for these procedures have been clearly 
identified in the literature
4
.  Using this model, in vivo studies are conducted to further the 
advancement of MS research. 
Risk Factors:  There are currently three known risk factors of multiple sclerosis, which 
including genetics, environment, and an immunological chance component.  Twin studies show 
that 25-40% of monozygotic twins both develop MS while there is only a 5% concordance rate 
in dizygotic twins
5
.  This demonstrates that genetic factors play a part in disease susceptibility, 
but it is not the only factor.  Additionally, the human leukocyte antigen (HLA) Class II gene has 
been found to have the highest association in MS patients
6
, also indicating a genetic component.  
Environmental factors, such as Epstein Barr virus (EBV) and smoking, play another role in 
susceptibility.  Almost all (99.5%) of MS patients have antibodies against EBV
7
.  However, 94% 
of the population has EBV antibodies, and they do not all develop MS
7
.  Therefore, this is 
another contributing risk factor.  It is also proven that there is a positive correlation between 
smoking before disease onset and developing MS
8
.  Finally, an immunological chance factor can 
be seen in the twin studies.  Only 25-40% of monozygotic twins both develop MS, though these 
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children have identical genetics and very similar environmental factors
5
.  Therefore, there is a 
“chance factor” because many immunological defects or challenges that shape the immune 
system need to occur at the same time to trigger disease onset.  These factors all play a role in 
disease susceptibility, but vitamin D is an additional factor that has promising implications for 
MS prevention.   
Vitamin D:  The association between vitamin D and MS has been evaluated since the 
1960’s when the first epidemiological study showed that there is an increase in MS prevalence 
farther from the Equator than closer to the Equator
9
.  This correlation has been shown in United 
Kingdom migrants.  Those who moved to Tasmania, a higher latitude, developed greater MS 
frequency than those who migrated to Queensland, a lower latitude, even though the migrants 
were from similar genetic backgrounds
10
.  The worldwide MS distribution correlates with UV 
exposure and vitamin D levels in the body.  Additionally, migration studies have shown that 
children over the age of 15 who move to higher latitudes develop the same MS risks as their 
counterparts in their original home
11
.  In contrast, children under the age of 15 will adapt risks 
from their new environment
11
.  This suggests that the role of vitamin D in MS risk is critical 
before puberty.  The data implies that there is a vitamin D mediated mechanism which causes an 
increased risk for MS early in life, even though disease onset occurs at 20-40 years of age. 
Vitamin D is commonly known to regulate calcium levels in the body, but it is also 
important in the immune system.  The pathway for vitamin D3 involves two biochemical 
reactions.  Epidermal skin layers have 7-dehydrocholesterol which is converted to cholecalciferol 
(vitamin D3) by ultraviolet light from the sun
12
.  The liver then hydroxylates cholecalciferol to 
calcifediol (25-hydroxyvitamin D3)
12
.  Calcifediol is then hydroxlated to calcitriol (1,25-
dihydroxycholecalciferol) by 25-hydroxyvitamin D3 1-alpha-hydroxylase (25(OH)D3-1α-
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hydroxylase) in the kidneys
13
.  Calcitriol is then the active form of vitamin D in the body.  In 
innate immunity, macrophages recognize infection or injury. Toll-like receptor (TLR) binding 
increases expression of vitamin D receptor (VDR) and the hydroxylase enzyme to increase the 
production of calcitriol
13
.  This active form of vitamin D can then interact with VDR on the cells 
which induces anti-microbial activity by releqasing cathelicidins and defensins.  These factors 
fight the insult and recruit additional immune cells
14
.  Along with this pathway, vitamin D 
influences the adaptive immune system in a variety of ways.  High levels of vitamin D are 
associated with decreased in T-cell proliferation
15
 and increased development of T-regulatory 
cells
16
.  There is also a shift in T-cell populations from Th1 to Th2 with a decrease in Th17 
cells
17
. Along with the effect on T-cells, vitamin D decreases B-cell differentiation
18
, production 
of inflammatory cytokines from monocytes
19
, and dendritic cell proliferation
20
.      
 Vitamin D also aids in the development of the CNS.  This is evident since both neurons 
and microglia express VDR, and 25(OH)D3-1α-hydroxylase is found in the CNS21.  This makes 
the production of calcitriol possible. Vitamin D aids in the release of nerve growth factor (NGF) 
and glial cell line-derived neurotropic factor (GDNF) to allow for differentiation of the cells in 
the CNS
21
.  Finally, vitamin D controls the calcium balance in the brain especially through 
calcium ion channels which aid in normal function of the CNS
21
.  Recent studies have shown 
that calcitriol can regulate neurotrophic levels in glial cells
22
.  These studies have led to the 
overall hypothesis that vitamin D has a neuroprotective function by decreasing inflammation in 
the CNS.  Vitamin D insufficiency is also seen in other neurological disorders including 
Parkinson’s disease, Schizophrenia, depression and cognitive decline,23 suggesting vitamin D is 
essential for normal CNS function.   
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However, even with this knowledge, it is still unknown how low vitamin D levels can 
increase MS susceptibility at a young age, even though the disease onset occurs 2-4 decades 
later in life. 
Microglia and IL-34:  Microglia are macrophages in the CNS, which are constantly 
surveying their immediate environment.  During development, microglia aid in CNS 
development.  Later in life, microglia respond to damage or infection in order to protect the 
CNS.  It is known that early-active MS lesions contain an activated form of microglia which 
express pro-inflammatory properties
24
.  It is now agreed that microglia activation is one of the 
key steps in MS disease pathogenesis.  Interleukin 34 (IL-34) is a newly discovered cytokine that 
is produced by neurons.  IL-34 has also been proven to be essential for microglia development 
and homeostasis
25
.  This implies that IL-34 aids in the development of an anti-inflammatory 
phenotype of microglia in the CNS.  Despite this research, it still unknown if an absence of IL-34 
would cause an increase in microglia activation.   
Hypothesis:  Although vitamin D has been extensively studied, it is still unknown how 
vitamin D affects neurons before disease onset in MS.  Since vitamin D would be the easiest 
manipulated risk factor in MS, we believe that investigating this topic is a critical step in 
prevention.  The correlation between MS onset and vitamin D deficiency before puberty must be 
fully investigated to understand MS pathogenesis and prevent disease onset.  It is known that 
increased vitamin D levels cause an increase in IL-34 production in endothelial cells
26
 and that 
vitamin D can prevent microglia activation by keeping them in an anti-inflammatory 
phenotype
27
.  Additionally, IL-34 production peaks during childhood and declines during 
adulthood
28
 making IL-34 a logical component in our hypothesized vitamin D mediated 
neuroprotective pathway for MS.  Our hypothesized model (Figure 1) shows the mechanism a 
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1a 
Figure 1: Our hypothesized mechanism showing the effects of vitamin D in a developing CNS.  Figure 1a 
shows a CNS with high vitamin D levels, and Figure 1b shows a CNS with low vitamin D levels.  
child’s CNS goes through during an insult to the CNS.  Although serious viral CNS infections 
such as meningitis and encephalitis can occur, mild CNS insults are common in children.  Many 
viruses do have some neurotropic capabilities and can cause minor inflammation in the CNS 
without any initial symptoms.  These types of insults are modeled in our hypothesized 
mechanism. 
We hypothesize that when there are high vitamin D levels during childhood (Figure 1a), 
neuron and myelin damage is prevented by vitamin D mediating high levels of IL-34 production 
from the neurons.  The IL-34 then binds to the microglia, causing them to become minimally 
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activated.  The low levels of pro-inflammatory cytokines produced help to fight off the infection 
without causing damage to the CNS.  This could then decrease the chances of T-cells becoming 
primed later in life by maintaining a healthy CNS.  However, when a virus penetrates the CNS 
and there are low levels of vitamin D (Figure 1b), the vitamin D receptors are not saturated 
which causes low levels of IL-34 to be released.  This prevents IL-34 receptors on microglia 
from achieving saturation.  We believe that this can lead to overly activated microglia which 
release high levels of pro-inflammatory cytokines and nitric oxide.  This inflammation causes 
myelin and neuronal damage, but there is not a detectable effect of this damage during 
childhood.  Later in life, this neurodegeneration could initiate auto-reactive T-cell formation 
because of the debris in the CNS and the decrease in CNS protection.  Therefore, this 
demyelination could increase the chance of T-cells becoming primed, increasing the risk of MS 
onset.  Therefore, our hypothesis states: Vitamin D increases IL-34 production, which directs 
microglia into an anti-inflammatory phenotype preventing neurodegeneration in a 
developing central nervous system.  
 
METHODS 
 Cell Line Cultures:  The mouse neuroblastoma (N2a) cell line was obtained from 
American Type Culture Collection (ATCC, Manassas, VA).  The cells were thawed and cultured 
for 7 days in Dubecco’s Modified Eagle’s Medium (DMEM) with 10% Fetal Bovine Serum 
(FBS).  The cells were then treated with 10nM retinoic acid for an additional 7 days.  
Differentiated cells were then washed and treated with calcitriol at 0nM, 10nM, 100nM, or 
1000nM for 24 hours.  After treatment, the cells were stored in 1mL of TRIzol at -80°C to be 
used for Quantitative Real-Time PCR.   
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Figure 2:  Pictured above is the experimental design for the BV-2 Microglia Cell Line treated with neuronal 
conditioned medium.  The N2a cells were treated with 0, 10, 100, or 1000 nM of calcitriol for 24 hours.  The 
medium was then used to treat the BV-2 Microglia Cell Line.  After incubation with LPS stimulation for 4 
or 18 hours, the supernatant and cells were examined for inflammatory markers using Real-Time PCR or 
ELISA.  Figure 2a is testing the effect of calcitriol while Figure 2b is also examining the effect of anti IL-34 
on the cell culture. 
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The murine microglial (BV-2) cell line was obtained from Dr. Godbout’s Lab (The Ohio 
State University, Columbus, OH).  These cells were thawed and cultured in microglia medium 
containing DMEM with 10% FBS.  The cells were then treated with the neuronal condition 
medium from the N2a cell line and cultured with LPS stimulation for either 4 or 18 hours in 
fresh medium (Figure 2a).  LPS stimulation lasted 4 hours for Quantitative Real-Time PCR and 
18 hours for ELISA.  The supernatant was collected and stored for ELISA analysis at -20°C and 
the cells were stored in 1mL of Trizol at -80°C to be analyzed with Quantitative Real-Time PCR.  
In the experiment where the cells were treated with anti IL-34, the anti IL-34 (2µg/ml) was 
added in with the neuronal condition medium (Figure 2b). 
Primary Cell Cultures: Primary neurons were isolated from wild-type B10.PL (Jackson 
Labs, Bar Harbor, Maine) neonatal mice at one day old.  The skin and skulls of the mice were cut 
in half to allow for removal of the entire brain.  The cortex was separated from the hippocampus, 
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and the meninges were removed.  The tissues were suspended in Phosphate Buffered Saline 
(PBS) during the rest of the process. The tissue was minced with a razor blade to approximately 
0.5mm
3
.  After washing three times with PBS, the cells were suspended in PBS (10mL).  
Digestion occurred in trypsin (0.025%) for 15 minutes at 37°C.  The digestion was stopped by an 
addition of 20mL of PBS.  The cells were repeatedly pipetted to breakdown the tissue further and 
passed through a cell dissociation sieve.  After, the suspended cells were centrifuged at 170 x g 
for 5 minutes at 37°C, PBS was removed and the cells were reconstituted in neuronal medium 
containing Neuronal Basal Medium with B-27 Serum-Free Supplement (2%), GlutaMAX
tm
-1 
(0.5mM), and gentamicin (20μg/mL).  The cells were plated at 200,000 cells per well in a 24 
well plate coated with Poly-L-lysine.  The cells were cultured for approximately 14 days with 
replacement of half of the medium every 3 days.  Calcitriol was used to treat the neurons at a 
concentration of 0nM, 10nM, 100nM, or 1000nM for 24 hours.  The supernatant was removed 
and the cells were stored in TRIzol at -80°C.    
Primary microglia were isolated from wild-type B10.PL neonatal mice at 0-4 days old.  
An incision was made through the skin and skull, and the brain was removed.  The brain samples 
were minced into 0.5mm
3
 size pieces using a scapula while the tissue was suspended in 10mL 
PBS.  Digestion occurred in trypsin (0.025%) for 15 minutes at 37°C with Deoxyribonuclease I 
(DNAse1, 1mL).  The solution had 15mL of PBS added to the culture to dilute the trypsin and 
centrifuged 170 x g for 5 minutes.  Once again, the cells were washed with PBS and spun down 
at 170 x g for 5 minutes.  The cells were resuspended in 15mL of microglial medium containing 
DMEM with FBS (20%), gentamicin (20μg/mL), L-glutamine (1%), and penicillin streptomycin 
(1%).  The particles were removed from the culture by a cell dissociation sieve.  Then, the cells 
were resuspended in 5mL of microglial medium per brain sample.  Cultures were plated in a 
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150cm
2
 flask with 5mL of resuspended cells and 20mL of microglial medium.  The medium was 
replaced every 3 days.  After approximately 10 days of culturing at 37°C, the cells were shaken 
at 80 x g for 3 hours at 37°C.  The supernatant was then plated on 24 well Poly-L-lysine coated 
plates at 1x10
5
 cells per well.  The cells were incubated at 37°C for 48 hours and treated with 
serum-free microglial medium, lipopolysaccharide (LPS, 0ng/mL or 10ng/mL), and IL-34 
(0ng/mL, 2ng/mL, or 10ng/mL) for 8 hours at 37°C.  A half hour before collection, adenosine 
triphosphate (ATP) was added to the culture to release produced Interleukin-1 beta (IL-1β)29.  
The supernatant was collected for ELISA analysis and stored at -20°C.  
 Enzyme-Linked Immunosorbent Assay (ELISA): Supernatants were collected from cell 
cultures as previously described.  The supernatants were analyzed for Interleukin 6 (IL-6), 
Interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and Interleukin 10 (IL-10).  A 
sandwich ELISA protocol was used.  In general, a purified monoclonal antibody specific for the 
protein was plated in the wells overnight.  After washing, samples or standards were added to the 
well to allow for antigen binding.  The standards were the recombinant protein of interest in a 
serial dilution.  After overnight incubation, the biotinylated detection antibody was added to bind 
to the antigen.  For the IL-6 ELISA, IL-6 purified anti-mouse capture antibodies and biotinylated 
goat anti-mouse detection antibodies from BD Biosciences were used.  The IL-6 standard was 
setup using recombinant proteins.  IL-1β TNFα, and IL-10 levels were examined using purified 
anti-mouse capture antibodies and biotinylated rat anti-mouse detection antibodies as well as 
standards from BioLedgend. After the detection antibodies were added, a substrate was used to 
cause an enzymatic reaction, resulting in color change if the antigen was present.  The substrates 
used were avidin-peroxidase for IL-6 and 3,3',5,5'-Tetramethylbenzidine (TMB) for IL-1β, 
TNFα, and IL-10.   An Emax Precision Microplate Reader was used to measure the enzymatic 
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reaction in the ELISA.  Between each antibody or antigen addition, the plate was washed using 
Wellwash 4 MK 2 with 1x PBS. The cytokine concentrations were calculated using SoftMax Pro 
Software in respect to the linear curve created by the standards.   
 Quantitative Real-Time Polymerase Chain Reaction (PCR):  RNA was isolated using the 
TRIzol Reagent Isolation Protocol.  The cells were stored in TRIzol as previously described with 
1ml of TRIzol per reaction. Chloroform (200µL) was added to each reaction, shaken for 15 
seconds, incubated for 3 minutes at 37°C, and then centrifuged at 12,000 x g for 15 minutes at 
4°C.  The upper aqueous phase was collected.  Isopropanol (500µL) was added to the aqueous 
phase of each reaction along with GlycoBlue (1µL).  The samples were incubated for 5 minutes 
and centrifuged at 12,000 x g for 10 minutes at 4°C.  Finally, the RNA pellet was washed with 
75% ethanol, centrifuged at 7,500 x g for 5 minutes at 4°C, and dried at 37°C. The pellets were 
resuspended in RNase-free water.  NanoDrop was used to find the concentration of the RNA.  
The concentrations were then used for the calculations reverse transcription.  The general 
procedure was conducted by reverse transcribing RNA (2.5 μg) into cDNA using the 
SuperScript
TM
 II Reverse Transcriptase manufacturer’s protocol.  Briefly, each reaction 
contained 100ng/uL random primer (1μL), 10mM dNTP (1μL), 5X First-Strand Buffer (4μL), 
0.1 M DDT (1μL), RNaseOUTTM (1μL), and SuperScriptTM II RT (1μL).  The reactions were 
temperature controlled by the Mastercycler.  The mRNA levels were determined by Real-Time 
PCR with SYBR Green RT-PCR Kit using the manufacturer’s protocol.  Each reaction contained 
the forward and reverse primer (0.5μL, 10nM) and 2x Master Mix (5μL).  The results were 
normalized to 1 using the hprt1 no treatment group.  The reactions were initiated and read with 
the Applied Biosystems ViiA 7 Real-Time PCR System.  The results were calculated using 2
-ΔΔCt
 
method and expressed as relative values. 
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Figure 3:  The mouse model used to delete VDR in the mice is under a Thy1 
promoter which is located only in the neurons.  This causes the neurons to 
fluoresce from the YFP tag, and the CreER
T2
 protein to translocate to the 
cytoplasm when tamoxifen is introduced.  Tamoxifen then fuses with the CreER
T2 
protein which allows the coupled proteins to relocate to the nucleus where it targets 
the VDR between the loxP sites. 
 Mouse Model:  We generated a transgenic mouse model with inducible VDR deletion 
specifically on neurons.  We developed this transgenic mouse by breeding VDR
f/f
 mice (Dr. Geert 
Carmeliet, University of Leuven, Belgium) and single-neuron labeling with inducible Cre-
mediated knockout (SLICK) mice from Jackson Laboratories
30
.  Cre recombinase-estrogen 
receptor T2 (Cre
ERT2
) is a fusion protein of estrogen receptor and cre-recombinase.  Cre-
recombinase recognizes flox/flox sites.  After one cross of these mice, we obtained SLICK f/+ 
mice, which contained only one loxP-flanked VDR allele.  The Cre
ERT2 
protein is normally 
located in the cytoplasm.  However when tamoxifen is administered, this causes translocation of 
the protein to the nucleus so 
it can bind to the loxP sites 
and cause deletion.  The 
Cre
ERT2 
proteins as well as 
an YFP tag are under the 
promoter of mouse Thy1 
gene, which is only found 
on neurons.  Therefore, this 
will cause a deletion of one 
VDR allele specifically in the neurons of the mice.  Additionally, the YFP tag can be used to 
identify the neurons in the SLICK mice.  The model used can be seen in Figure 3.  
 Immunohistochemistry:  The mice were perfused using 4% paraformaldehyde (PFA) with 
pH 9.4.  The brain and spinal cord were removed.  The tissue samples were incubated in 10%, 
20%, and then 30% sucrose each for 24 hours.  The tissues were frozen into Optimal Cutting 
Temperature (O.C.T) Compound and sectioned into 10µm slices.  The slides were stored at -
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20°C.  The tissues were incubated in 0.4% Triton-X with PBS for 30 minutes to permeablize the 
sample.  The tissues were then incubated in 1% BSA, 0.4% Triton-X, 5% goat serum, and 
0.001% sodium azide in PBS for 1 hour as a blocking solution.  The primary antibody, vitamin 
D-receptor (VDR) rabbit polyclonal IgG, was then added at a concentration of 1:500 in blocking 
solution and was incubated overnight.  The slides were then washed three times for 10 minutes 
each in PBS.  The secondary antibody, Alexa Flour chrome 546 goat anti-rabbit IgG, was added 
at a concentration of 1:4000 in blocking solution for 1 hour.  The slides were again washed three 
times for 10 minutes each.  The slides were fixed with VECTASHIELD Hard Set Mounting 
Medium with DAPI.  Pictures were taken at 40x with Olympus 8X41 microscope.   
 EAE Induction:  Myelin oligodendrocyte glycoprotein (MOG) peptide fragment 35-55 
(50ug) and Proteolipid Proteins 139-151 (50µg) with adjuvant complete freund (CFA, 50µl) and 
Mycobacterium tuberculosis (final concentration of 1mg/ml) was mixed for 20 minutes to form 
an emulsion.  The mice were immunized with the emulsion (25µl) by subcutaneous injection into 
four sites, medial to each leg.  Pertussis toxin (100ng, 200µl/injection) was then administered to 
each mouse.  Clinical EAE development occurred approximately 10 days after the initial 
immunization.  The mice were scored on a scale from 0-6.  The scoring system states: 0 = no 
clinical disease, 1 = limp tail, 2 = moderate hind limb weakness, 3 = severe hind limb weakness, 
4 = complete hind limb paralysis, 5 = quadriplegia or premorbid state, and 6 = death from 
disease.  The Institutional Animal Care and Use Committee at The Ohio State University 
Wexner Medical Center approved all animal protocols.   
 Statistical Analysis:  GraphPad Prism software was used to perform the statistical 
analysis.  The unpaired T-test was used for all statistical analysis except EAE disease course.  
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Figure 4: N2a cells and primary neurons were treated with various 
concentrations of calcitriol.  Figure 4a shows that in N2a cells, we observed a 
direct correlation between an increase in calcitriol and IL-34.  Figure 4b 
examined the effected of calcitrol on primary neurons.  There was an 
increase in IL-34 expression until 100 nM of calcitriol.    
Il34 N2A cells
0 10
 
10
0 
10
00
 
0.0
0.5
1.0
1.5
2.0
2.5
Calcitriol (nM)
IL
3
4
 (
fo
ld
 c
h
a
n
g
e
)
 4b 4a 
** 
* 
EAE significance was evaluated using the Mann-Whitney U test.  One asterisk indicates a p-
value <0.05, two asterisks is a p-value <0.01, and three asterisks is a p-value <0.001. 
 
RESULTS 
 Vitamin D Increases IL-34 Levels:  To investigate the initial step of the hypothesized 
mechanism, neurons were treated with calcitriol and analyzed for IL-34 production.  N2a cells, a 
Neuroblastoma cell line, were differentiated into “neuron-like” cells with retinoic acid for 7 
days.  Calcitriol was then used to treat the cells for 24 hours.  The cells had a dose dependent 
increase in IL-34 production as the concentration of calcitriol was increased using Quantitative 
Real-Time PCR (Figure 4a).  To verify that calcitriol induces IL-34 in neurons, the same 
procedure was used to measure 
the IL-34 production of 
primary neurons from wild-
type neonatal mice.  The 
primary cells were cultured for 
14 days and treated with 
calcitriol for 24 hours.  There 
was an increase in IL-34 
production which peaked at 100nM of calcitriol in primary neuron cultures (Figure 4b) 
confirming that vitamin D can induce IL-34 production in neurons.   
IL-34 Inhibits Inflammatory Response:  Our next question addressed IL-34 modulating 
microglia phenotype. Primary microglia were isolated from neonatal mice and cultured for 48 
hours.  The cells were then placed in serum free medium and treated with LPS (0ng/mL or 
2a 2b 
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Figure 5: Primary microglia were treated with IL-34 at 
various concentration.  There was a significant decrease in the 
production of IL-6, IL-1β, TNFα, and IL-10 cytokines when 
analyzed by ELISA. 
10ng/mL) and IL-34 (0ng/mL, 2ng/mL, or 10ng/mL) for 8 hours.  LPS is a Toll-like receptor 4 
(TLR4) agonist that activates microglia and induces pro-inflammatory cytokine production.  The 
supernatant was collected and used to analyze cytokine production via ELISA.  Levels of IL-6, 
TNFα, IL-1β, and IL-10 
production were analyzed.  
There was no change in the 
groups without LPS 
stimulation.  However, 
when stimulated with LPS, 
there was a dose-dependent 
decrease in IL-6, TNFα, IL-
1β, and IL-10 (Figure 5).  
IL-34 reduced all cytokine 
expression, both pro-
inflammatory (IL-6, TNFα, 
and IL-1β) and anti-
inflammatory (IL-10), indicating that IL-34 suppresses microglia activation and cytokine 
production.  This suggests that IL-34 promotes a resting phenotype in microglia. 
Vitamin D Inhibits Inflammatory Response:  We next analyzed whether calcitriol 
induction of IL-34 by neurons induces microglia activation.  N2a cells were treated with 
calcitriol for 24 hours.  The neuronal conditioned medium was collected and used to treat BV-2 
microglia.  These microglia were also activated with LPS.  The supernatant was collected for 
ELISA and the RNA was extracted for Quantitative Real-Time PCR.  After analysis, there was 
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Figure 6:  BV-2 microglia were treated with neuronal conditioned medium from calcitriol treated 
neurons.  Figure 6a was analyzed from ELISA and showed a decrease in IL-6 as the concentration of 
calcitriol used to treat the neurons was increase.  Quantitative Real-Time was used to analyze ARG1, 
MHCII, iNOS, and HO-1.  All results are compared to hprt1.  Figure 6d includes the addition of anti 
IL-34.  There was no longer a decrease in IL-6 production when anti IL-34 was added to the medium.  
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no difference in any of the groups without LPS stimulation.  There was a decrease in the 
production of IL-6 as the concentration of calcitriol to treat the N2a cells was increased from 
0nM to 1000nM (Figure 6a) in the LPS stimulated group.  In addition, this experiment was 
repeated with 1000ng/ml of LPS and there was significance at 100nM and 1000nM of calcitriol.  
There was also a decrease in major histocompatibility complex (MHC) class II and inducible 
nitric oxide synthase (iNOS).  The mRNA levels of anti-inflammatory markers arginase 1 
(ARG1) and heme oxygenase 1 (HO-1) were increased as the concentration of calcitriol used to 
treat the neurons was increased.  These results are shown in Figure 6b and Figure 6c.  To 
determine if IL-34 was responsible for the decreased cytokine production, anti IL-34 was added 
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Figure 7: Wild-type and SLICK f/+ mice were perfused and the tissue was stained for VDR (red) and DAPI (blue).  YFP 
(green) signaling can also be in the SLICK mice, tagging each of the neurons.  Figure 7a shows a WT f/f mouse, and figure 
B is a SLICK f/+ mouse. After quantification of VDR positive cells, we found a significant decrease of VDR in the SLICK 
f/+ mice.  Figure 7c shows the average percent of VDR positive cells using 5 images for each group. 
 
7a 7b 7c 
to the neuronal conditioned medium before it was used to treat the microglia.  There was not the 
same decrease in IL-6 as previously seen; illustrating that IL-34 was the cytokine that mediated 
the change in IL-6 production (Figure 6d). 
SLICK f/+ Mice Have Decreased Vitamin D Receptor:  The SLICK mice were crossed 
with VDR f/f mice to obtain SLICK f/+ mice which had inducible vitamin D receptor deletions 
specifically on neurons.  The cells were then stained for VDR (red) and DAPI (blue).  There is 
also an autofluorescent YFP tag (green) on the SLICK mice.  The YFP tag was in the SLICK 
mice under the Thy1 promoter which is located only in neurons.  The cells with vitamin D 
receptor were counted in both wild-type and SLICK f/+ mice, and there was a significant 
decrease in the number of cells with of vitamin D receptor in the SLICK mice compared to the 
wild-type mice.  An example of the samples that were used in quantification can be seen in 
Figure 7a and Figure 7b.  In the wild-type mice 77.6% of the cells were VDR+ while only 
44.8% were positive in the SLICK f/+.  Therefore, there was a significant decrease in cells that 
were VDR positive in the SLICK mice compared to the wild-type mice.  The percentage of VDR 
positive cells can be seen in Figure 7c.  
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Figure 8: There was a significant increase in EAE severity in the SLICK 
f/+ mice when compared to the WT f/f and f/+ mice.  Each group had 
100% penetrance of disease.  The results shown are from two independent 
experiments each with significance. 
 
 
Decreased Vitamin D Signaling in Neurons Increases Disease Severity:  To determine if 
decreased VDR signaling in neurons may increase susceptibility to CNS autoimmunity, the 
SLICK f/+ and wild-type 
mice were evaluated for 
disease severity using the 
EAE model.  The SLICK 
f/+ mice were fed a 
tamoxifen chow diet from 3-
5 weeks of age to cause 
VDR deletion during early 
life, and then EAE was 
induced at 7 weeks of age.  
All of the mice in the experiment did develop disease.  Although there was no significant change 
in disease onset, there was a significant increase in disease severity of the SLICK f/+ mice when 
compared to the wild-type mice (Figure 8).  This suggested that decrease VDR signaling in 
neurons enhances CNS autoimmunity. 
DISCUSSION 
Though the first epidemiological study conducted by Acheson in 1960 proved there was a 
correlation between MS and childhood vitamin D levels
9
, the mechanism by which vitamin D 
prevents MS later in life is still unknown.  We propose a mechanism where vitamin D stimulates 
IL-34 production in neurons, which mediates an anti-inflammatory phenotype in a developing 
CNS.  If the CNS becomes damaged during childhood, this could aid in the process of priming 
T-cells that could cause MS onset later in life.  In addition, the damage could make the CNS 
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more susceptible to an MS attack.  Therefore, by more fully understanding this mechanism, we 
could work to prevent MS onset in susceptible patients.  The data shown here does support 
our hypothesis; however, additional experiments are needed in order to completely prove 
this hypothesis.   
Initially, we showed that by treating a neuronal cell line with calcitriol there was a dose 
dependent increase in mRNA levels of IL-34.  Calcitriol is the form of vitamin D that is 
circulating throughout the body.  Therefore, the response of these cells can occur without the 
need of synthesizing or activating the vitamin D.  In the primary neuronal cultures, there was an 
increase in IL-34 as the concentration of calcitriol increased.  However, it was not dose-
dependent.  This result can be attributed to the fact that normal levels of calcitriol in a mouse are 
between 10nM and 100nM.  Therefore, at 1000nM, the vitamin D is above physiological levels, 
and the vitamin D receptors are most likely completely saturated.  We hypothesize that this is the 
reason we did not see the increase in the levels of IL-34 mRNA at 1000nM of calcitriol.  In the 
future, we would like to repeat these experiments and investigate IL-34 production through 
ELISA.  
Our next experiment further investigated the second part of our hypothesized mechanism.  
Primary microglia were directly treated with IL-34 in order to investigate their change in 
cytokine production.  The ELISA data did indicate that IL-34 directs the microglia into an anti-
inflammatory phenotype, since there was a significant decrease in pro-inflammatory cytokines 
IL-6, IL-1β, and TNFα.  All of these cytokines are mediators in the immune response.  The 
decrease in these pro-inflammatory cytokines in the CNS indicates the environment is not 
stressed, and it is not producing harmful products such as nitric oxide.  There was also a decrease 
in IL-10, which is normally considered an anti-inflammatory cytokine.  The decrease in this 
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cytokine indicates that there could be an overall decrease in cytokine production in the 
immediate environment.  IL-34 is presumed to be in a surveying state which would not induce 
cytokine production.  In multiple sclerosis, it is known that low IL-10 levels cause an increase in 
TNFα, which leads to inflammation31.  However, since we saw a decrease in TNFa, we do not 
believe this IL-10 to be causing this inflammatory response.  Even with this knowledge, the role 
of IL-10 needs to be more fully evaluated in order to understand this mechanism.  Additional 
experiments need to be conducted to see if there is an overall decrease in cytokine production or 
an increase in other anti-inflammatory cytokines.    
 
The final in vitro experiment investigated the overall mechanism by combining the 
methods of the two previous experiments.  The neuronal cell line was treated with calcitriol and 
cultured to allow for the hypothesized IL-34 to be produced.  The neuronal conditioned medium 
was then used to treat a microglial cell line.  After treatment, ELISA was used to investigate the 
cytokine production.  As previously seen in the IL-34 treated primary microglia, there was a 
decrease in IL-6 production as the concentration of calcitriol used to treat the neurons was 
increased.  We believe that this change was due to the increase in IL-34 production that occurred 
when a higher concentration of calcitriol was used to treat the neuronal cultures. There was also 
a decrease in MHC class II and iNOS.  The expression of MHC class II is normally on immune 
antigen presenting cells
32
 and is up regulated in response to foreign antigens such as LSP.  A 
decrease in this marker indicates that there was reduced activation of the microglia.  
Additionally, iNOS is known to be involved in immune disease pathogenesis and is defined as an 
inflammatory mediator
33
.  High levels of nitric oxide, from iNOS, are known to play a role in 
MS progression.  Nitric oxide causes damage to the blood-brain barrier, axonal degeneration, and 
demyelination from oligodendrocyte damage
34
.  Therefore, iNOS could be a key factor in myelin 
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damage during childhood.  A decrease in this mRNA exemplifies that there is an anti-
inflammatory response being activated.  Although IL-10 in the previous experiment indicated 
that there could be an overall decrease in cytokine production, we did find an increase in anti-
inflammatory markers arginase-1 and HO-1.  Arginase is an important anti-inflammatory marker 
in the CNS because of its neuroprotective function
35
.  In addition, HO-1 is normally induced 
during oxidative stress and can decrease free oxygen species to aid in the inflammatory 
response
36
.  Therefore, we saw a decrease in pro-inflammatory cytokines as well as an increase 
in anti-inflammatory cytokines.  Overall, this indicates that the system has an anti-inflammatory 
phenotype when treated with calcitriol to increase IL-34 levels in the cells. These experiments 
need to be repeated in primary neurons and primary microglia in order to completely prove the 
hypothesis.  In addition, we confirmed that the production of IL-6 in these cultures was due to 
IL-34 production, because anti IL-34 neutralized the IL-6 response.  Adding anti IL-34 to the 
culture would decrease IL-34 production even in the high calcitriol samples.  This assures that 
there is not another cytokine in the medium that is inducing changes in the inflammatory 
response.  Therefore, anti IL-34 needs to be added to the primary cultures as well.  The anti IL-
34 antibody should stop the changes in cytokine production and prove that IL-34 is mediating 
this response.  
 The in vitro experiments help to show the steps of the hypothesized mechanism in a 
controlled setting.  However, the cell cultures do not necessarily reflect the processes that occur 
in vivo.  This is why it was important for us to continue these experiments in an animal model.  It 
is not easy to achieve a mouse model with vitamin D deficiency for a variety of reasons.  If 
vitamin D is completely removed from the mouse since birth by systemically deleting vitamin D 
receptor, the mouse does not grow normally.  After birth the mice appear similar to wild-type 
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mice.  However, after weaning the mice have hypocalcemia, infertility, impaired bone formation, 
and do not survive past 15 weeks of age
37
.  Mice that develop in a low vitamin D environment 
also have distortion in brain shape, reduced differentiation, and lower neurotropic factors
38
.  
Adult mice even have decreased attentiveness and behavioral sensitivity
38
.  Therefore, we would 
not be able to induce EAE in these mice to study the effects of decreased vitamin D levels.  Also, 
feeding mice a vitamin D deficient diet is not enough to decrease vitamin D levels in the body.  
Mice can obtain vitamin D from the light in the housing facility despite the fact that most of their 
bodies are covered in fur. Furthermore, vitamin D deficiency also has a significant effect on the 
immune response in these mice.  This is why we found it important to create a mouse model 
which had inducible vitamin D receptor deletion specifically on neurons. 
Breeding VDRf/+ and SLICK CreER
T2
 mice created our transgenic mouse model.  After 
tamoxifen administration, the SLICK f/+ mice were found to have significantly decreased VDR 
levels while still appearing to be healthy mice.  The vitamin D receptors positive cells were 
counted using a stain that marked the nucleus of all cells in the tissue.  This could potentially 
include astrocytes, microglia, oligodendrocytes, ependymal cells, as well as neurons.  Therefore, 
this count needs to be repeated by staining only neurons in order to more accurately identify the 
decrease of VDR specifically on the neurons.   
Finally, EAE was induced in the SLICK f/+ mice at 7 weeks of age.  When compared to 
the control mice, the SLICK f/+ had a significant increase in disease severity.  EAE is a highly 
studied mouse model of MS and induction is well defined in literature
4
. However, we induced 
sub-optimal EAE by only having one injection of the pertussis toxin.  This allowed us to see the 
effects of low vitamin D without having a large number of mice die from the disease.  EAE is a 
T-cell mediated autoimmune disorder.  This shows that vitamin D signaling in neurons is playing 
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a role in the CNS inflammation, which is consistent with our proposed hypothesis.  Our 
hypothesis does state that vitamin D affects susceptibility in a developing CNS.  We deleted 
VDR from 3-5 weeks old, when the mice are still consider juvenile.  Typically, 8 to 9 weeks old 
is considered an adult mouse.  In the future, we want to identify the exact point in development 
when vitamin D affects EAE disease severity.  Therefore, we plan to repeat this experiment 
multiple times and change the age at which the mice have VDR deleted.  We anticipate the most 
severe disease to be seen before the mice undergo puberty, because the epidemiological 
migration data states that this is when vitamin D is most important in humans to prevent MS
11
. 
Other EAE studies have also seen changes in disease severity when vitamin D was altered in 
adolescent rats
39
.  In addition, we preformed our experiments in SLICK f/+in order to represent a 
vitamin D deficient central nervous system.  This model most accurately represents a MS 
susceptible person, since most individuals do have some levels of vitamin D.  SLICK f/f mice 
could also be tested in order to study a model with an even greater decrease of VDR.  We do 
need to be careful with this model because vitamin D is important for normal CNS development.  
Therefore, these mice could have additional neurological problems which we do not initially 
anticipate.  Although the data seems to correlate with the in vitro model, we cannot conclude that 
this change is mediated by the same mechanism without examining IL-34 levels.  It would be 
difficult to identify IL-34 levels in these mice by Quantitative Real-Time PCR because IL-34 is 
produced by a variety of cells in the CNS.  Therefore, we would most likely not see a change in 
IL-34 levels by only altering the production in neurons.  Instead, we plan to perform intravenous 
injections to introduce IL-34 back into these mice after the VDR deletion, and then induce EAE.  
With the supplementation of IL-34, we hypothesize that these mice will have a similar disease 
course to the wild-type mice.  The IL-34 that is administered should replace the IL-34 that would 
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be reduced from the VDR deletion.  This experiment would be the final experiment needed to 
prove the proposed hypothesis.   
 Studies on vitamin D as a mediator in immunological diseases have been increasing 
during the last few years.  The focus on vitamin D is due to the increase in number of children 
and adults with vitamin D deficiency.  The increase in vitamin D deficiencies has been attributed 
to the increased concerns about UV light as a risk factor for skin cancer
40
.  The concern for 
dieting and eating less calories has also lead to an increase in individuals who do not consume 
milk products which are a major source of vitamin D
40
.  In addition, fewer individuals have jobs 
which required them to be outside for long periods unlike a few decades ago
40
.  This change in 
human vitamin D levels has led to vitamin D studies on a wide variety of diseases such as 
Parkinson’s disease, Alzheimer’s disease, heart disease, and a variety of cancers. 
The hypothesis that vitamin D could be associated with multiple sclerosis is not a new 
idea to the field.  Currently, vitamin D is being investigated as a therapeutic supplement for MS 
in a clinical trial
41
.  Despite this ongoing research, it is important to realize that our hypothesis 
stated here addresses vitamin D as a risk factor for MS, not a treatment method.  Other risk factor 
studies have also been conducted to evaluate vitamin D changes before EAE onset.  Adzemovic 
conducted a similar study in rats where the diets were either supplemented or deprived of 
vitamin D
39
.  The diet changes occurred in pre-and early post-natal mice by altering the mothers’ 
diets as well as in juvenile/adolescent and adult rats.  The mice that were supplemented with 
vitamin D during adolescence did have decreased EAE disease severity supporting our overall 
hypothesis.  Our project builds on these ideas.  Although vitamin D supplementation is the end 
goal of the experiment, vitamin D deficiency does need to be studied in order to fully understand 
our proposed mechanism.  This study did not see a change in rats with vitamin D deficient 
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diets
39
, but we believe this is due to the vitamin D the mice were synthesizing naturally during 
development.  We hope our project can add to these ideas by providing a convincing model 
which has decreased VDR.  In addition, we ultimately hope to find the exact time point in 
development which causes changes to EAE disease severity as well as prove that IL-34 is 
mediating this change. 
 As previously stated, vitamin D is only one of the many risk factors that are currently 
known for MS.  However, if vitamin D is proven to be a major contributing risk factor, it would 
be the easiest to manipulate in children of at risk populations.  Children who live at latitudes 
above 40
o
, premature infants, and individuals with darker skin complexion have increased risk of 
vitamin D deficiency
42
.  One study found that greater than 50% of children hospitalized in the 
pediatric intensive care units during the fall and winter were found to be vitamin D deficient or 
insufficient
42
.  If these risk factors are combined with the risk factors for MS such as a genetic 
history of multiple sclerosis, history of EBV, and smoking, a specific population could be 
targeted to help prevent multiple sclerosis.  In this population, vitamin D supplements could be 
administered at a young age.  This supplementation would be easy to begin, because vitamin D 
already exists as a vitamin supplement in pill form.  In addition, injections of vitamin D are 
available which are more effective and longer lasting.  The cost of these supplements would be 
much lower than any other multiple sclerosis drug on the market, and they are already known to 
have minimal side effects.  Very high levels of vitamin D do have negative side effects, 
especially in children and young adults.  This would make it important to monitor these 
individuals while they receive the vitamin supplementation, especially during childhood.  
Overall, vitamin D could be easily and cost effectively administered to prevent multiple sclerosis 
in susceptible populations. 
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CONCLUSION 
 This study attempts to prove the mechanism that can explain the correlation between MS 
susceptibility and vitamin D insufficiency in early life.  Our hypothesis is that vitamin D in the 
CNS signals to produce IL-34 which keeps microglia in their surveying state without causing 
excessive damage in a developing CNS insult.  Our data supports our hypothesis.  However, 
more data collection is needed to fully prove this hypothesized mechanism.  This data sets the 
foundation for additional experiments to understand the relationship between vitamin D 
insufficiency and the risk of CNS autoimmunity.  By proving this mechanism, we will one day 
be able to supplement at risk patients with vitamin D in order to help prevent the lifelong and 
devastating effects of multiple sclerosis. 
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